Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase I/II study of HH2853 in relapsed/refractory non-Hodgkin lymphoma or advanced solid tumors
CTR20201548Phase 2Active
- Sponsor
- Haihe
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HH2853 in non-Hodgkin lymphoma (NHL), Nonhematologic neoplasms, follicular lymphoma (FL), peripheral T-cell lymphoma (PTCL), epithelioid sarcoma (ES), sponsored by Haihe. Started Nov 2020; status: active.
02
Drugs
HH2853
03
Conditions
non-Hodgkin lymphoma (NHL)Nonhematologic neoplasmsfollicular lymphoma (FL)peripheral T-cell lymphoma (PTCL)epithelioid sarcoma (ES)
Beyond the preview
Go deeper on CTR20201548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201548.